drugset / Trial / NCT07081503
Phase 1 Study of ADX-626 in Healthy Participants
RandomizedParallel-groupDouble-blindTreatment
Summary
This first-in-human study will evaluate the safety and tolerability of ADX-626 in healthy participants. The study will also look at how ADX-626 interacts with the human body (the pharmacokinetics and pharmacodynamics of ADX-626).
Timeline
- Start
- 2025-08-12
- Primary completion
- 2027-01-22
- Completion
- 2027-01-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADX-626 | Unknown | — | — |
Indications
No indication recorded.